The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience

Br J Haematol. 2015 Oct;171(2):281-284. doi: 10.1111/bjh.13377. Epub 2015 Mar 30.
No abstract available

Keywords: CD20 monoclonal antibodies; chronic lymphocytic leukaemia; lenalidomide; relapsed/refractory.

Publication types

  • Letter